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Abstract
The human pregnancy begins with fertilization and implantation. As the embryo evolves and develops within the
uterus of the mother, the placenta is formed. The placenta is a transient organ that develops to meet and accommodate specific needs during pregnancy. Its two major functions are the exchange of nutrients and gases between
the mother and fetus and its role as an endocrine unit. Through the production and release of many hormones
the placenta works to regulate the many necessary physiological changes in the mother in order to maintain the
pregnancy, meet the needs of the developing fetus and prepare the mother’s body for birth. The placenta releases
both steroid and peptide hormones. Each hormone has specific target tissues and is used to signal a specific response. These responses work to facilitate a healthy pregnancy and a healthy outcome for the newborn.
Introduction

Pregnancy, specifically human gestation, begins even before the
release of a mature oocyte and ends with parturition, approximately 9 months later. Pregnancy is an amazing phenomenon that
integrates many complex physiological processes and ultimately
results in reproduction of the human species. During this vital
time the placenta is formed as a transient organ, and it continues
to play a critical role in maintaining the health of both the embryo/
fetus and the mother up until the time of delivery. It continuously
evolves to meet the changing needs of the developing fetus within
its maternal physiological environment (Linzer and Fisher, 1999).
The placenta has two major functions. The first function is the
exchange of metabolic and gaseous products between maternal
and fetal bloodstreams. In this way the placenta is able to provide oxygen and nutrients, as well as remove waste products for
the developing fetus. The second function is hormone production
(Linzer and Fisher, 1999). The hormones produced and released
by the placenta assist in triggering the maternal physiological
changes necessary to meet the needs of the fetus, as well as the
changes needed to prepare the mother for the specific needs of
the baby after birth. These changes are widespread amongst the
various systems of the mother and are coordinated largely by circulating hormones. Some of these hormones are hormones that
are commonly found circulating within the adult (non-pregnant)
female in various concentrations. Others are hormones unique
to the pregnant female only and are not otherwise found in the
body. This role makes the placenta an important endocrine organ
necessary for the successful continuation of a pregnancy (Sadler,
2012) (Linzer and Fisher, 1999).

Background

In order to understand how the placenta functions, it is important
to first understand how it is formed, beginning with fertilization.
During ovulation, one mature oocyte is usually released by the
ovaries and is transported into the uterine tube by the sweeping
action of tubal fimbriae. When all biological conditions are suitable, and if a sperm meets the released egg, then fertilization of the
embryo generally takes place in the fallopian tubes. The fertilized
egg then goes through a series of cell divisions eventually creating

a tightly grouped ball of sixteen cells called a morula. On approximately the third or fourth day after fertilization the morula begins
to travel down the fallopian tube, eventually reaching the uterus.
A fluid filled cavity begins to appear within the morula, and it develops into a blastocyst. The inner cell mass of the blastocyst will
form the embryoblast, which gives rise to tissues of the embryo
proper, and the rest of the cell mass, which surrounds the inner
cells and blastocyst cavity, will form the trophoblast, which later
contributes to the placenta (Sadler, 2012).
By this time, the zona pellucida, which is the glycoprotein membrane that surrounded the ovum, has disappeared and implantation into the uterus begins as the blastocyst continues to evolve.
This occurs on the sixth day after fertilization, as trophoblastic
cells begin to penetrate between the epithelial cells of the uterine mucosa (Sadler, 2012). At this time, the mucosa of the uterus
is in the secretory phase of the menstrual cycle, in response to
progesterone that is released by the corpus luteum that remains
following ovulation. The corpus luteum is maintained for the first
few weeks of pregnancy by the release of hCG from the trophoblast and it continues to release specific hormones that affect the
uterus and allow implantation to occur. Eventually, however, the
corpus luteum degenerates and is replaced by the placenta, which
then becomes responsible for continued hormone production
(Cole, 2012).
In preparation for implantation, the glands and arteries of the
uterine endometrium become coiled and three distinct layers
form in the endometrium. The formation of the placenta then results from mutual interaction of the trophoblast and the endometrium. Under normal circumstances, the blastocyst implants along
the anterior or posterior wall of uterine endometrium, where
it becomes embedded between the openings of the glands and
continues to root itself more deeply into the endometrium until
it becomes completely embedded and almost entirely covers the
uterine wall, on approximately the eleventh or twelfth day. (Sadler,
2012).
At the time of implantation the development of the placenta begins, as the trophoblast continues to develop by differentiating in
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to two layers. These layers include the cytotrophoblast and the
syncytiotrophoblast (Carlson, 2004). The cytotrophobast, which
is the inner layer, consists of mononucleated cells that migrate
and fuse to form a multinucleated syncytiotrophoblast, which will
function as the endocrine unit of the placenta (Alsat et. al. 1997).
The syncytiotrophoblast, which is a highly invasive tissue, soon
surrounds the entire blastocyst and begins to insert small projections between uterine epithelial cells. It continues to spread
towards the basal lamina underlying the endometrium, forming
a flattened trophoblastic plate, eventually eroding maternal tissue, actually penetrating the basal lamina, and making its way into
the endometrial stroma. During this time, isolated vesicles, called
lacunae form in the trophoblast, and as the syncytiotrophoblast
erodes maternal vessel walls, maternal blood begins to fill the
lacunae. As this process continues, and as maternal blood flows
through the trophoblastic system, a basis for utero-placental circulation is established (Carlson, 2004).
As the trophoblast continues to grow and develop, so does the
embryoblast, as it differentiates into two layers. A thin membrane
then lines the inner surface of the cytotrophoblast, forming the
exocoelomic cavity or the primitive yolk sac. A new layer of cells
appears between the trophoblast and this membrane, and forms
a matrix of loose connective tissue known as the extraembryonic
mesoderm. It lies immediately internal to the entire trophoblast,
as well as around the layers of the embryoblast (including the yolk
sac and amniotic cavity). Cavities soon develop and then merge to
form a single large cavity that surrounds the yolk sac and amniotic cavity. This cavity is the chorionic cavity. The chorionic plate
encompasses the part of the extraembryonic mesoderm that
borders the fetal side of the placenta, along with its trophoblast.
The connective stalk is then the only place where the chorionic
plate traverses through chorionic cavity. With the development of
blood vessels as well as other elements, the connective stalk becomes the umbilical cord which will form the connection between
placenta and embryo (Sadler, 2012).
By the beginning of the third week, the cells of the cytotrophoblast, which continue to proliferate towards the endometrium,
eventually penetrate the syncytiotrophoblast and form column-like structures that are surrounded by a syncytial layer.These
are the primary villi. Mesodermal cells then penetrate the core of
the primary villi to form secondary villi. Mesodermal cells then
differentiate into blood cells and blood vessels, forming a capillary network that makes contact with capillaries developing in the
chorionic plate, the connecting stalk, and eventually the intraembryonic circulatory system. The villous system is getting ready for
the time that the heart begins to beat, at approximately the fourth
week of development (Sadler, 2012).
The villi on the embryonic pole continue to grow and develop, giving rise to the chorion frondosum, which is a bushy chorion area,

36

while the villi on abembryonic pole eventually degenerate. The
portion of the endometrium that lies over the embryonic pole
becomes abundant with lipids and glycogen and becomes firmly
attached to the chorion. This is the decidua basalis. The remaining
portion of the endometrium that lies over the abembryonic pole
also degenerates. Together, the chorion and the decidua basalis
make up the placenta, which becomes the only portion of the
chorion where the exchange of maternal and fetal materials takes
place. Maternal blood from the lacunae of the syncytiotrophoblast
begins to fill the intervilli spaces of the chorion. Septa continue to
form from the decidua, protruding into intervilli space, but never
actually reaching the chorion.This, in turn, forms compartment-like
structures, called cotyledons, that are not fully separated by the
septa. It is in these compartments that high pressure arteries bring
oxygen-rich blood towards the villous trees that have developed
in the chorion and then back towards endometrial veins. The intervillous spaces of a mature placenta contain approximately 150
mL of blood, which is replenished about 3-4 times per minute.
At all times there is a layer of syncytium that separates maternal
blood from fetal tissue, as part of the placental membrane. The
villi serve to increase surface area and are the primary site of
placental exchange (Sadler, 2012).
As the pregnancy progresses, the placenta continues to grow, covering approximately fifteen to thirty percent of the internal surface
of the uterus (Carlson, 2004).This growth serves to accommodate
the ever growing needs and demands of the developing fetus and
ensures sufficient transfer of nutrients. Continuous proliferation,
differentiation, and fusion of cytotrophblast is what maintains and
expands this syncytial interface throughout pregnancy as syncytiotrophblast cells are shed into maternal circulation when they
reach the end of their life cycle (Forbes and Westwood, 2010). A
clear relationship has been established, with a direct relationship
between placental weight and fetal weight throughout pregnancy.
This points to the ever important role that the placenta unit plays
in fetal growth, through its various functions (Alsat et. al. 1997).
One major function of the placenta at this point, as mentioned,
is the exchange of nutrients and wastes. Through the process of
diffusion, gases, such as oxygen, carbon dioxide, and carbon monoxide are exchanged between mother and fetus. Additionally, the
exchange of nutrients and electrolytes, such as amino acids, fatty
acids, carbohydrates, and vitamins are also diffused through the
placental barrier. Although immunity is beginning to develop, maternal antibodies are also transported from the mother to the
fetus via the placenta (DeChemey et. al. 2013).
The seconds major function of the placenta is the production of
hormones which serve to maintain the pregnancy, to uphold an
optimal environment within the physiology of the mother, and to
prepare the mother for birth. The release of hormones by the
placenta is an endocrine communication system that stimulates
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specific reactions on target tissue, facilitating changes necessary
for the state of the pregnancy. The myometrium, which lies just
beneath the endometrium is a vital tissue during the pregnancy
period, and it is a critical target for fetal placental communication.
The major hormone changes that occur through these placental
communications are noted specifically in the increased levels of
estrogen, progesterone, and chorionic gonadotropin. However,
there are other hormones as well, that participate in this complex
system of fetal-maternal interaction, although on a smaller scale,
(DeChemey et. al. 2013).

Steroid Hormones

Over the years much research has been done in order to determine the actual role of the placenta in hormone production.
One group of hormones produced by the placenta are the steroid
hormones estrogen and progesterone. Various studies have been
done to verify that it is actually the placenta that produces the
elevated levels of these hormones during pregnancy. Studies in
which pregnant women underwent surgery to remove the corpus
luteum at various stages of pregnancy resulted in a substantial
amount of lost pregnancies when the corpus luteum was removed
before the eighth week. Removal of the corpus luteum after the
eighth week did not result in abortions. These results suggest that
after the eight week there are a significant amount of placental
secretions (Csapo et. al. 1972). Furthermore, women with ovarian
failure who participated in an ovarian assisted reproduction program demonstrated increased peripheral blood progesterone and
estradiol levels by the fifth week of pregnancy. These levels were
above the background levels achieved by the constant replacement regimen. With the absence of ovarian function, this study
also suggests the role of the placenta in maintaining proper hormone levels and sustaining pregnancy (Scott et. al. 1991).

Estrogen

Estrogen is a steroid hormone that is produced in the syncytiotrophoblast of the placenta (Alsat et. al. 1997), with the placenta becoming the primary source of this hormone approximately during
the ninth week of pregnancy. Estrogen levels remain low during
the first trimester of pregnancy and then progressively increases,
remaining elevated, until labor.
An important role of estrogen during pregnancy is the synthesis
of contractile proteins in the myometrium, as well as local concentration of contraction associated proteins, such as oxytocin and
connexin-43 (Cx-43). It also increases prostaglandin production
and regulates the expression of nitrate oxide synthase isoforms.
Estrogen, therefore, plays a significant role in preparing the uterus
for labor contractions and delivering the baby. Although estrogen
assists in the priming of the myometrium for labor, it is important
to note that the estrogen alone is not clinically effective in the
induction of labor. Furthermore, a pregnancy can continue to exist
and labor is still possible, even amongst women with low levels

of circulating estrogen (Ticconi et. al. 2006). However, in cases of
low placental estrogen synthesis, changes that generally occur in
the reproductive tract before parturition, such the ripening of the
cervix, generally do not occur (Strauss et. al. 1996). The actions of
estrogen are therefore efficient in conjunction with other factors
(Ticconi et. al. 2006).
Other significant functions of estrogen are the stimulation of uterine growth, as well as development of the mammary glands, in
preparation for birth.The development of the mammary gland begins initially at puberty with estrogen exposure and is completed
in the third trimester of pregnancy (Sadler, 2012).

Progesterone

Progesterone is another major steroid hormone that is produced
by the placenta. Until approximately ten weeks gestation, progesterone is produced by the corpus luteum that remains after
ovulation. In a normal menstrual cycle where pregnancy does
not occur, the corpus luteum degenerates soon after ovulation.
However, when pregnancy does occur, hCG that is released from
the trophoblast stimulates the maintenance of the corpus luteum,
which, in turn, releases progesterone. This prevents the shedding
of the endometrium lining (Cole, 2012) and allows for proper
implantation (Kumar and Magon, 2012). Progesterone continues
to be released by the corpus luteum until approximately week
eight to ten gestation. It then continues to be produced by the
placenta, specifically by the syncytiotrophoblasts of the chorion, in
response to the uptake of maternal lipoproteins. The expression
of low density lipoproteins appears to be directly related to the
presence of progesterone (Ticconi et. al. 2006).
Progesterone acts in multiple ways to decrease the contractility of
the myometrium lining of the uterus. By decreasing Cx-43 expression, stimulating nitrate oxide expression, and down-regulating
calcium channels and oxytocin receptors, progesterone serves to
maintain a state of dormancy during most of the pregnancy. Three
progesterone receptor subtypes, PR-A, PR-B, and PR-C have been
identified. Only PR-B mediates the expression of progesterone responsive genes, whereas PR-A represses this activity. During most
of pregnancy, PR-A levels are low. At the time of labor, however,
PR-A levels increase drastically, as do PR-A receptors, thereby
suppressing the effects of placental progesterone during this crucial time and allowing uterine contractions to progress, despite
maternal circulating progesterone (Ticconi et. al. 2006).
Although progesterone has a quiescent effect on the uterus, another primary function of this hormone is its effect on the cervix. Progesterone has been found to have a direct effect on the
length of cervix, and in this way serves to prevent preterm labor.
Studies have shown that a shortened cervix in the second trimester is often an early indicator that preterm labor will occur. Both
natural and synthetic progesterone have been found to have a
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strengthening and lengthening effect on the cervix, and are thereby often effective in postponing preterm labor. Local withdrawal
of progesterone at the cervical level appears to have the opposite
effect of softening and effacing the cervix in preparation for delivery. Although exact mechanisms are unknown at this time, progesterone has been shown to have an effect on mucus plug formation
and possibly contributes to improved antimicrobial activity in this
area (Campbell, 2011).
Another important function of progesterone is its contribution
to mammary gland development. Although the mammary glands
begin to develop at puberty, continued development and preparation for lactation is still necessary. Progesterone had been found
to be associated with ductal proliferation and lobuloalveolar differentiation. This enables the mammary glands to produce and
secrete milk after delivery (Lydon et. al 2000).

Peptide Hormones
Human Chorionic Gonadotrophin

Human Chorionic Gonadotrophin (hCG) is a pregnancy hormone
that is critical to both the establishment and maintenance of the
pregnancy, playing a role in multiple facets of the pregnancy process. HCG is a glycoprotein hormone that is similar in structure
to luteinizing hormone (LH). It is synthesized and secreted primarily by the syncytiotrophoblasts, and it binds to specific hCG
receptors in target tissues (Ticconi et. al. 2007). It is detectable
early in pregnancy, as soon as eight to nine days after ovulation
and levels continue to rise until the final weeks of pregnancy.
Emerging evidence continues to demonstrate a wider range of
biological effects that hCG has on various tissues types than was
previously recognized.
One of the major functions of hCG during the first trimester
is the prevention of luteolysis and stimulation of progesterone
production in the corpus luteum (Cole, 2012). As mentioned, this
ensures that the uterus, which is generally in the secretory stage
of the menstrual cycle at the point of fertilization, maintains an
optimal state for implantation to occur (Ticconi et. al. 2007). By
sustaining the production of progesterone, hCG indirectly works
to maintain the decidual cells of the endometrium, thereby preventing aptosis. At this point, hCG also functions to promote
angiogenesis in the uterine vasculature, allowing for improved
circulation and maximum blood supply to the area as the placenta
forms. HCG has also been shown to control growth and development of the umbilical cord in this way (Cole, 2012). HCG, which
is considered to be similar to thyroid stimulating hormone (TSH),
mildly stimulates the thyroid gland to produce more thyroid hormone throughout pregnancy. This is especially important, as the
thyroid hormone passes through the placenta and is critical for
brain and nervous system development in the fetus. At approximately twelve weeks, the fetus begins to produce its own thyroid
hormone (Kilby et. al. 2005).
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After the first trimester, hCG continues to play a pivotal role in
maintaining the pregnancy through various mechanisms. Studies
have shown that hCG strongly induces the proliferation of myometrial smooth muscle cells. This contributes to the continuous
growth of the uterus throughout pregnancy, providing an optimal
environment for the simultaneous continuous growth and development of the fetus. HCG also assists in inhibition of uterine contractility. Just like progesterone, HCG has been found to directly
decrease expression of connexin 43. It has also been found to
reduce the expression of PR-A, further reducing uterine contractility in this way. HCG also decreases intracellular concentration
of free calcium in the smooth muscle cells, thereby inhibiting
the amplitude of response to oxcytocin-stimulated contractions.
Additionally, hCG is the only pregnancy hormone that has been
found to inhibit the expression of phosphodiesterase (PDE) 5 enzyme, which is involved in the hydrolysis of cAMP and cGMP that
regulate myometrial relaxation. This further assists in modulating
uterine contractility and in inhibition of preterm labor (Ticonni et.
al. 2007). During the final weeks of pregnancy, levels of hCG tend
to drop, in preparation for delivery. This drop allows for increased
responsivity to prostaglandin and oxytocin, enabling contractions
to occur (Ticonni et. al. 2006).
Another important function of HCG is its effect on the fetal membranes. A study conducted by Ticconi et al (2007) demonstrated
increased expression of the isoform of nitric oxide synthase in
response to hCG.This, in turn, may contribute to the relaxed state
of the uterus as well as to immune system activity in the fetal
membranes, although this has not yet been proven (Ticconi et.
al. 2007). Additionally, hCG promotes anti-macrophage inhibitory
factor, thereby preventing rejection of the foreign fetal tissue by
the mother throughout pregnancy (Cole, 2012). Additionally, new
studies have found hCG receptors in many fetal organs and tissues.
This may indicate that hCG also plays a role in fetal growth during
pregnancy. These receptors are then removed upon partuition. It
is also interesting to note the hCG receptors are also found in
the hippocampus, hypothalamus, and brain stem of the mother.
This may explain the presence of nausea and vomiting that often
occurs in pregnancy, as receptors detect this hormone in maternal
circulation (Cole, 2012).
Another form of hCG is the sub-type hyperglycosylated hCG.
Although it is an autocrine, and not a hormone, hyperglycosylated
hCG promotes cytotrophobast cell growth during the early stages
of pregnancy. HCG then promotes the fusion and differentiation
of these cells to syncytiotrophoblast cells, leading to the formation of the villous system. This, combined with angiogenesis and
umbilical cord formation, becomes the fetal maternal interface of
the placenta (Cole, 2012).

Placental Hormones

Chorionic Somatomammotrophin

Chorionic somatomammotrophin (hCS), also known as placental
lactogen hormone (LH) is a lactogenic protein that is also produced by the syncytiotrophoblasts of the placenta (Ayala et. al.
1989). It is considered to be similar, immunologically, to pituitary
growth hormone, and it effects fetal growth in an indirect manner, according to present studies. It is secreted almost exclusively
into maternal circulation, with only small amounts crossing into
fetal circulation. It can first be detected in the maternal blood
stream at approximately six weeks gestation, and it plays a significant role in maternal metabolism, as maternal hCS concentrations
tend to rise throughout pregnancy with irregular fluctuations
(Handwerger and Freemark, 1987). During approximately the last
month of pregnancy, hCS levels usually level off. It has been found
that depressed levels of maternal hCS correlate with intrauterine
growth retardation and are associated with high risk pregnancies. It should also be noted that levels of hCS have been noted
to increase in direct proportion to increased placental volume
(Macmillan et. al. 1976).
HCS works in a manner that is similar to human growth hormone
(hGH). It works to effect both carbohydrate and protein metabolism in the mother. Like hGH, hCS enhances insulin secretion and
impairs glucose tolerance in the mother, thereby facilitating and
increasing the supply of glucose and energy that is available to be
delivered to the fetus. HCS also facilitates an increase in lipolysis
in adipose tissue of the mother. This helps to ensure that more
free fatty acids are available for energy use by the mother instead
of glucose. In this way even more glucose is available for use by
the fetus. Furthermore, ketones that are formed from the free
fatty acids can cross the placenta and can be used by the fetus.
Large amounts of hCS released from the second month of pregnancy onward appear to be related to breast, nipple, and alveolar
growth, although exact mechanisms are uncertain (Handwerger
and Freemar, 1987).

Placental Growth Hormone

During the early stages of pregnancy, until approximately 20 weeks,
pituitary growth hormone (GH), which originates in the pituitary
gland of the mother, is the primary growth hormone found in
maternal circulation. Then, from approximately twelve to twenty
weeks, until term, placental growth hormone gradually replaces
pituitary growth hormone, which eventually becomes undetectable in maternal circulation. Placenta growth hormone is similar
in structure to pituitary growth hormone, but is produced in the
syncytiotrophoblasts of the placenta. Additionally, it binds to cell
receptors with similar affinity to pituitary GH. PGH has a relatively short half-life and there is a rapid fall in serum concentrations
within one hour after removal of the placenta following delivery
(Lacroix et. al. 2002).

Placental GH is secreted in a continuous, non-pulsatile fashion
into maternal circulation only and is not detected in fetal blood
at all. This continuous secretion of placental GH into maternal
circulation has critical implications for maternal physiological adaptation to gestation, as it impacts metabolism. Although it does
not have a direct impact on fetal growth, this hormone works to
stimulate gluconeogenesis, lipolysis, and anabolism in the liver and
other organs of the mother. In this way it serves to increase nutrient availability for the fetal-placental unit, indirectly affecting fetal
growth. This is especially important during the last few months of
pregnancy when fetal growth is most prominent. Furthermore,
intrauterine growth restriction has been found to be associated
with decreased levels of placental GH, indicating the crucial role
this hormone plays for the developing fetus. Both the rate of synthesis, as well as maternal blood levels of this hormone, have been
found to be directly related to growth of the placenta (Lacroix et.
2002,) (Alsat et. al. 1997).
Placental GH demonstrates high somatogenic activity, and just like
pituitary GH, it has been found to induce weight gain. It has also
been found to be one of the key regulators of maternal Insulin Like
Growth Factor 1 (IGF1). Additionally, placental GH concentration
has been found to decrease in response to high levels of glucose.
As the syncytiotrophoblast, which regulates the expression of
Glut1, a major glucose transporter, comes into direct contact
with maternal blood circulation, elevated glucose levels may be
detected by these cells. The sycncitiontrophoblast then respond
to variations in maternal blood glucose by modifying placental GH
secretion. Recent data on the expression of placenta GH and its
receptors in the villi of the trophoblast open new questions as to
other roles that this hormone may play (Lacroix et. al. 2002).

Insulin-Like Growth Factor

The presence of various growth factors (GF) in maternal circulation is generally increased throughout gestation and specific
growth factors, such as insulin-like growth factor (IGF), have been
found to be linked to fetal growth. Two specific IGF types, IGF 1
and IGF 2 have been identified, and both have been found to be
positively correlated to fetal birth weight (Forbes and Westwood,
2010). These peptide hormones work by binding to specific receptors on target tissues in order to mediate a variety of metabolic and mitogenic processes. Although IGF 1 and IGF 2 each
have individual receptors, both typically bind to IGF 1 receptor
(IGF1R) through the aid of binding proteins.This receptor is found
in all cell types of the placenta, including trophoblast, villous endothelium, and mesenchymal cells and is thought to regulate the
mitogenic effects of IGF 1 and IGF 2. IGF binding proteins that are
generally found in abundance in the area of the placenta are also
correlated to fetal growth (Hiden et. al. 2009).
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Although exact mechanisms remain unclear, it appears that one
way in which IGFs affects fetal growth is through its effect on the
placenta. Placentally derived IGF2 have been found to have a role
in promoting trophoblast invasion, thereby promoting placental
growth and function. Studies have also shown that exposure of
the syncytial surface to IGFs enhanced cytotrophoblast proliferation and differentiation. Because placenta growth has been closely
associated with fetal growth, continuous proliferation of cytotrophblast cells in order to maintain the placenta is crucial. By stimulating placental growth, IGF works to enhance nutrient transport
and delivery to the fetus, thereby promoting fetal growth (Forbes
and Westwood, 2010)

Vascular Endothelial Growth Factor

Vascular endothelial growth factor (VEGF) is an essential hormone for placental growth, and it has a significant impact on
coordinating angiogenesis, blood flow, and the breakdown of the
extracellular matrix in the placenta. It is found to be present in
the blood vessels of both placenta and the umbilical cord, and it is
hypothesized that it acts as a paracrine hormone on fetoplacental
circulation. In this way it contributes to the growth and maintenance of the placenta as well as delivery of oxygen and nutrients
to the fetus. This hormone further assists in vasodilation, as there
is no sympathetic innervation in the spiral arteries and in the placenta.These functions are vital for the growth and development of
the fetus, as adequate nutrient supply is crucial. Studies have noted
a decreased vascular response to VEGF in cases of intrauterine
growth retardation.This indicates the importance of the effects of
this hormone, and further research is needed to verify the exact
mechanisms of the decreased responsivity in these cases, and how
this can be prevented (Krukier and Pogorelova, 2006) (Szukiewicz
et. al. 2005).

Relaxin

Relaxin is a peptide hormone that is considered to be similar to
insulin. It is produced and secreted during pregnancy, at first by
the corpus luteum in the ovary, and then later by the decidua,
endometrium, and trophoblast of the placenta. Highest levels of
relaxin are detectable in the first trimester of pregnancy. Then,
levels tend to drop and stabilize. It mediates its effect both on
the reproductive organs, as well as on other organs in the body
(Dschietzig and Stangl, 2003).
This peptide hormone originally received its name due to its relaxing and elongating effects on the interpubic ligament. It further
assists in softening the cervix and the tissues of the birth canal,
thereby facilitating the passage of the fetus during parturition.This
was later attributed to the ability of relaxin to reduce cervical collagen concentration and increase collagen solubility during pregnancy. Estrogen was then found to further enhance these effects
(Dschietzig and Stangl, 2003).

40

As years went on, more research has been conducted to try to
uncover some other important functions of this hormone. Relaxin
has been found to have regulating effects on oxytocin secretion,
although data is conflicting in regard to exactly how. Other effects
of relaxin include its ability to inhibit uterine contractile activity
throughout gestation. However, this effect has been found to be
mild in humans. Relaxin also promotes the growth and differentiation of the mammary parenchyma and stroma in preparation for
lactation. It is further considered essential for the development of
mammary nipples (Dschietzig and Stangl, 2003).

Conclusion

The placenta is a transient organ that is formed during pregnancy
for the purpose of nourishing the developing embryo/fetus and
for maintaining an optimal physiological environment within the
mother in order to sustain the pregnancy. During this approximately ninth month period, the placenta undergoes continuous
growth and change in order to accommodate the ever changing
needs of the mother and fetus. One of the major roles of this
organ is its function as an endocrine unit with its release of many
hormones which have widespread effects on the maternal tissues
and organs. This is what allows the pregnancy to continue and
thrive, ultimately resulting in parturition and birth of the fetus.

Placental Hormones
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